Annals of Diagnostic Pathology
Volume 15, Issue 4 , Pages 273-277 , August 2011

Malignant mixed müllerian tumor of primary peritoneal origin

  • Margaux Kanis, MD

      Affiliations

    • School of Medicine, University at Buffalo, Buffalo, NY 14214, USA
    • ,
  • Joshua P. Kesterson, MD

      Affiliations

    • Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 716 845 8376; fax: +1 716 845 7608.
    • ,
  • Stuti Shroff, MD, PhD

      Affiliations

    • Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    • ,
  • Shashikant Lele, MD

      Affiliations

    • Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    • ,
  • Paulette Mhawech-Fauceglia, MD

      Affiliations

    • Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

References 

  1. Dictor M. Malignant mixed mesodermal tumor of the ovary: a report of 22 cases. Obstet Gynecol. 1985;65:720–724
  2. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006;100:128–132
  3. Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer. 2008;18:22–29
  4. Muntz HG, Rutgers JL, Tarraza HM, Fuller AF. Carcinosarcomas and mixed mullerian tumors of the fallopian tube. Gynecol Oncol. 1989;34:109–115
  5. Weber AM, Hewett WF, Gajewski WH, Curry SL. Malignant mixed mullerian tumors of the fallopian tube. Gynecol Oncol. 1993;50:239–243
  6. Clement PB, Zubovits JT, Young RH, Scully RE. Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol. 1998;17:211–222
  7. Peters WA, Kumar NB, Andersen WA, Morley GW. Primary sarcoma of the adult vagina: a clinicopathologic study. Obstet Gynecol. 1985;65:699–704
  8. Garamvoelgyi E, Guillou L, Gebhard S, Salmeron M, Seematter RJ, Hadji MH. Primary malignant mixed Mullerian tumor (metaplastic carcinoma) of the female peritoneum. A clinical, pathologic, and immunohistochemical study of three cases and a review of the literature. Cancer. 1994;74:854–863
  9. Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC. Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): report of a case with five-year disease-free survival after surgery and chemoradiation and a review of literature. Acta Oncol. 2005;44:756–760
  10. Ober WB, Black MB. Neoplasms of the subcoelomic mesenchyme; report of two cases. AMA Arch Pathol. 1955;59:698–705
  11. Mikami M, Kuwabara Y, Tanaka K, Komiyama S, Ishikawa M, Hirose T. Malignant mixed mullerian tumor of primary mesenteric origin. Int J Gynecol Cancer. 2005;15:1249–1253
  12. Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 1993;50:347–351
  13. Ferrie RK, Ross RC. Retroperitoneal mullerian carcinosarcoma. Can Med Assoc J. 1967;97:1290–1292
  14. Costa MJ, Khan R, Judd R. Carcinoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Arch Pathol Lab Med. 1991;115:583–590
  15. de Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol. 1993;24:132–142
  16. Meis JM, Lawrence WD. The immunohistochemical profile of malignant mixed mullerian tumor. Overlap with endometrial adenocarcinoma. Am J Clin Pathol. 1990;94:1–7
  17. Ohno S, Kuwano H, Mori M, Sakata H, Mori A, Shinohara K. Malignant mixed mesodermal tumour of the peritoneum with a complete response to cyclophosphamide. Eur J Surg Oncol. 1989;15:287–291
  18. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;93:336–339
  19. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol. 2002;85:459–463
  20. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007;105:657–661
  21. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109:323–328
  22. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007;12:999–1006
  23. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. [corrected] J Clin Oncol. 2007;25:2755–2763
  24. du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, et al. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol. 2005;96:444–451

☆ Conflict of Interest Statement: The authors have no conflicts of interest to declare.

PII: S1092-9134(10)00041-9

doi: 10.1016/j.anndiagpath.2010.03.004

Annals of Diagnostic Pathology
Volume 15, Issue 4 , Pages 273-277 , August 2011

Article Tools

* Image Usage & Resolution